BCAB vs. AURA
BCAB (BioAtla, Inc.) and AURA (Aura Biosciences, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, BCAB returned -72.68%/yr vs -17.71%/yr for AURA. At a 0.19 correlation, their price movements are largely independent.
Performance
BCAB vs. AURA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BCAB achieves a -87.42% return, which is significantly lower than AURA's 28.81% return.
BCAB
- 1D
- -1.38%
- 1M
- -3.25%
- YTD
- -87.42%
- 6M
- -89.34%
- 1Y
- -82.66%
- 3Y*
- -72.68%
- 5Y*
- -71.95%
- 10Y*
- —
AURA
- 1D
- 1.01%
- 1M
- -7.63%
- YTD
- 28.81%
- 6M
- 16.23%
- 1Y
- 14.15%
- 3Y*
- -17.71%
- 5Y*
- —
- 10Y*
- —
BCAB vs. AURA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
BCAB BioAtla, Inc. | -87.42% | -3.97% | -75.97% | -70.18% | -57.97% | -32.22% |
AURA Aura Biosciences, Inc. | 28.81% | -33.70% | -7.22% | -15.62% | -38.16% | 20.43% |
Correlation
The correlation between BCAB and AURA is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.16 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Oct 29, 2021 | 0.19 |
Fundamentals
BCAB:
-$1.10
AURA:
-$1.79
BCAB:
$0.00
AURA:
$0.00
BCAB:
-$12.46M
AURA:
-$574.00K
BCAB:
-$67.70M
AURA:
-$115.85M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BCAB vs. AURA — Risk / Return Rank
BCAB
AURA
BCAB vs. AURA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BioAtla, Inc. (BCAB) and Aura Biosciences, Inc. (AURA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BCAB | AURA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.87 | ||
| Sortino ratioReturn per unit of downside risk | -1.71 | ||
| Omega ratioGain probability vs. loss probability | 0.90 | 1.09 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | -0.88 | 0.45 | -1.33 |
| Martin ratioReturn relative to average drawdown | -1.34 | 0.84 | -2.18 |
Loading charts...
Drawdowns
BCAB vs. AURA - Drawdown Comparison
The maximum BCAB drawdown since its inception was -99.91%, which is greater than AURA's maximum drawdown of -80.31%. Use the drawdown chart below to compare losses from any high point for BCAB and AURA.
Loading charts...
Drawdown Indicators
| BCAB | AURA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.91% | -80.31% | -19.60% |
Max Drawdown (1Y)Largest decline over 1 year | -94.57% | -31.26% | -63.31% |
Max Drawdown (3Y)Largest decline over 3 years | -98.31% | -61.11% | -37.20% |
Max Drawdown (5Y)Largest decline over 5 years | -99.85% | — | — |
Current DrawdownCurrent decline from peak | -99.90% | -71.80% | -28.10% |
Average DrawdownAverage peak-to-trough decline | -84.85% | -59.12% | -25.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 61.78% | 16.81% | +44.97% |
Volatility
BCAB vs. AURA - Volatility Comparison
BioAtla, Inc. (BCAB) has a higher volatility of 22.93% compared to Aura Biosciences, Inc. (AURA) at 13.36%. This indicates that BCAB's price experiences larger fluctuations and is considered to be riskier than AURA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BCAB | AURA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 22.93% | 13.36% | +9.57% |
Volatility (6M)Calculated over the trailing 6-month period | 101.14% | 41.40% | +59.74% |
Volatility (1Y)Calculated over the trailing 1-year period | 133.41% | 55.98% | +77.43% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 118.50% | 69.49% | +49.01% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 115.02% | 69.49% | +45.53% |
Dividends
BCAB vs. AURA - Dividend Comparison
Neither BCAB nor AURA has paid dividends to shareholders.
Financials
BCAB vs. AURA - Financials Comparison
This section allows you to compare key financial metrics between BioAtla, Inc. and Aura Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
BCAB and AURA have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BCAB has higher volatility (22.93%) compared to AURA (13.36%). In terms of maximum drawdown, BCAB dropped -99.91% vs AURA's -80.31%.
AURA currently has the higher Sharpe Ratio (0.25 vs -0.62), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BCAB and AURA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer